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A B S T R A C T
E-cadherin, a 120 kDa transmembrane protein, plays an important role in malignant progression and tumour differ-
entiation. The loss or reduction in E-cadherin expression has been found in several tumours including laryngeal squa-
mous cell carcinoma. The present study aimed to investigate the prognostic implications of changes in expression of the
E-cadherin in laryngeal carcinoma. E-cadherin expression was determined by immunohistochemistry in paraffin- em-
bedded tissue specimens from 80 patients. A staining score was given based on the percentage of cells stained (0–100%).
E-cadherin expression varied greatly among tissue samples from 2 to 72 (median 25). Using the median expression of
E-cadherin as a cut- off, 41 (51.3%) tumours were classified in the »low E-cadherin« group and the rest, 39 (48.7%) tu-
mours, consisted the »high E-cadherin« group. We found significant differences in the staining scores of E-cadherin be-
tween those tumours with and without nodal metastases (p=0.025) and advanced clinical stage (TNM stage III and IV)
(p=0.014). The results of a stepwise logistic regression analysis showed that E-cadherin staining score and the location
of primary tumour were independent predictors of nodal metastases. The immunohistochemical determination of E-ca-
dherin expression may be useful instrument to characterise the metastatic potential of carcinomas. Larger studies are
needed to confirm the role of E-cadherin expression in predicting the behavior of laryngeal squamous cell carcinomas.
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Introduction
Laryngeal carcinoma represents 2.4% of new cancer
diagnoses annually in men1. The majority of these tu-
mours are squamous carcinoma (more than 90%) rang-
ing from poorly to well differentiated. The presence of
lymph node metastasis is the most important prognostic
factor in patients with laryngeal carcinoma and deter-
mines the treatment. The detection of lymph node me-
tastasis is still difficult at the time of diagnosis. Physical
examination, ultra-sound, magnetic resonance imaging
or computed tomography are mainly based on the size of
the lymph nodes and detect the late macroscopic nodal
metastases, but microscopic ones evade recognition. Da-
ta from literature indicate that 4–40% of patients with
laryngeal carcinoma and clinically negative neck lymph
nodes have indeed occult metastases2,3. That’s why it is
very important to find markers that could predict the
metastatic behavior of the primary tumour.
The development of human cancer is multiple steps
processes that induce tumour invasiveness and metastasis.
It has long been known that cell–cell adhesion is com-
monly reduced in human cancers. Cell adhesion mole-
cules mediate cell-cell and cell-matrix interactions. Adhe-
sion molecules consist of five major families: integrins,
cadherins, immunoglobulin gene superfamily (IgSF), se-
lectins and CD44. Cadherins are a group of calcium-de-
pended adhesion molecules. They have an extracellular
domain (N-terminal) and a cytoplasmic tail (C-terminal)
which interacts with the cytoskeletal proteins via intra-
cellular proteins termed catenins (a, b, g) forming the
E-cadherin-catenin complex4. There are four cadherin
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subclasses: epithelial cadherin (E-cadherin), placental
cadherin (P-cadherin), neural cadherin (N- cadherin) and
liver cell adhesion molecule (L-CAM)5,6. E-cadherin is ex-
pressed in all adult human epithelial tissues. It is a 120
kD peptide assigned to chromosome 16q22. Downregu-
lation of E-cadherin reduces cell-cell adhesion and gap
junction-mediated communication7. Several immunocy-
tochemical studies have shown that reduced expression
of E-cadherin is associated with invasive growth pat-
terns, poor differentiation, metastases, and aggressive
behavior of carcinomas.
The clinical significance of altered expression of E-ca-
dherin remains controversial in laryngeal carcinoma.
The present study aimed to investigate the prognostic




A total of 80 patients were included in the present
study, 40 of them with glottic and 40 with supraglottic tu-
mour. All patients were treated for laryngeal squamous
cell carcinomas (SCCs) at the Clinic of Otorhinolaryngo-
logy and Maxillofacial Surgery of the Clinical center of
Montenegro in Podgorica from 2001 to 2008. Both groups,
glottic and supraglottic, consisted of 20 patients with
early (TNM stage I and II) and 20 patients with advanced
(TNM stage III and IV) cancer. The clinical information,
including sex, age, histologic grade, primary tumour (T)
classification, nodal (N) status, TNM stage, and oncolo-
gical outcome, were obtained retrospectively from clini-
cal records. Pathological staging was determined accord-
ing to the 6th TNM Classification of malignant tumours
of the International Union against Cancer8. Patients
with second primaries or who had received primary ra-
diotherapy and/or chemotherapy were not considered.
All selected patients underwent primary partial (58 ca-
ses) or total laryngectomy (22 cases) as primary treat-
ment. Neck dissection was also performed in 29 cases. In
the analysis of clinical data we have defined poor onco-
logical outcome as recurrence of disease or occurrence of
metastasis after treatment. Disease-free survival was
calculated from the period of treatment completion until
the date of tumour relapse. Mean follow-up time (calcu-
lated in months from treatment completion to the last
otolaryngological control) was 28.4 months (median 27
months, range 6–60 months). Clinicopathologic charac-
teristics of the selected patients are shown in Table 1.
The study was approved by the Center for science and
researchs of the hospital. We did not need additional in-
formed consent to use the specimens in this study be-
cause only archived material was used.
Immunohistochemistry
Eighty specimens of formalin- fixed, paraffin- embed-
ded tissue blocks were cut into 3-mm sections by a
microtome. All included samples originated from com-
plete resection material. The slides were then dewaxed,
hydrated, and washed with TRISbuffered saline (TBS).
This process was followed by microwave treatment for 20
min in citrate buffer (pH=6.0) to retrieve the antigens
present. After blocking endogenous peroxidase activity
in water with 0.3% H202 for 30 min, tissue sections were
incubated with anti- E-cadherin antibody (Clone NCH-
38 diluted 1:50, DAKO, Denmark) for 30 min and mouse
antigen was applied for 30 min. Immunodetection was
performed with the Envision system, DAKO Autostainer,
model VL1. Diaminobezidine (DAB) was used as a chro-
mogen for 10 min. The slides were then counterstained
with hematoxylin. Appropriate positive and negative
controls were included in all reactions.
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TABLE 1
CLINICOPATHOLOGIC CHARACTERISTICS OF 80 PATIENTS
WITH LARYNGEAL SQUAMOUS CELL CARCINOMA






£65 years 60 75














Stage I 19 23.8
Stage II 21 26.2
Stage III 32 40.0
Stage IV 8 10.0
Histological grade (HG)
HG I 34 42.5
HG II 45 56.3
HG III 1 1.2
Loco-regional recurrence
L-R rec. no 60 75
L-R rec. yes 20 25
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Evaluation of E-cadherin expression
The slides were viewed randomly, without clinical
data, by one of the authors. The staining was predomi-
nantly membranous with some cytoplasmatic staining. A
staining score was given based on the percentage of cells
stained (0–100%). All stained cells were considered posi-
tive regardless of the intensity of the staining. For the
purposes of this study, we classified the patients as low
expressers (E-cadherin expression below the median of
the staining scores) and high expressers (E-cadherin ex-
pression above the median).
Statistical analysis
The correlation between the clinicopathologic param-
eters and the expressions of E-cadherin were evaluated
using chi-square (c2) test and Kruskal-Wallis test. The
role of each possible prognostic factor (univariante anal-
ysis) and the joint effect of all these factors (multiva-
riante analysis) was explored using the multivaniate lo-
gistic regression analysis. A p value less than 0.05 was
considered to be significant in all statistical analyses. p
values in the range 0.10>p³0.05 were considered as indi-
cating a statistical trend. All statistical analyses were
conducted with SPSS 13.0 (Statistical Package for Social
Sciences, SPSS Inc., Chicago, IL, USA).
Results
Expression of E-cadherin was evaluated in 80 pa-
tients, from which 61 (76.2%) were males and 19 (23.8%)
females. The mean age of the patients were 59.3±9.23
years, ranging from 37 to 81 years. Median age was 58
years. There were 40 (50%) cases with glottic and 40
(50%) cases with supraglottic tumour. The tumour stages
were T1 to T4, N0-N2, M0. Forty patients had early can-
cer (Stage I or II) and 40 had advanced cancer (Stage III
or IV). Twenty of 80 patients developed loco-regional ma-
lignancy recurrence (7 local recurrences, 13 recurrences
to neck lymph nodes).
E-cadherin expression was associated with the cell
membrane and varied greatly among tissue samples from
2 to 72 (median 25). The mean expression of E-cadherin
in considered study group was 28.86 (standard deviation
[SD]=19.14). Using the median expression of E-cadherin
as a cut- off, 41 (51.3%) tumours were classified in the
»low E-cadherin« group (Figure 1) and the rest, 39 (48.7%)
tumours, consisted the »high E-cadherin« group (Figure
2). The correlation of E-cadherin expression with clinico-
pathologic parameters is summarized in Table 2.
The expression of E-cadherin was not associated with
age, sex, the primary tumour’s location and differentia-
tion grade. There were significant differences in the
staining scores of E-cadherin between those tumours
with and without nodal metastases (p=0.025) and ad-
vanced clinical stage (TNM stage III and IV) (p= 0.014).
The differences in expression of E-cadherin between
cases presented with tumour recurrence and the cases
without recurrence were near statistically significant
(p=0.053). The expression of E-cadherin in advanced T3-
T4 tumours was lower than in T1- T2 tumours but result
is near statistically significant (p=0.079).
The results of a stepwise logistic regression analysis
showed that E-cadherin staining score and the location
of primary tumour were independent predictors of nodal
metastases (Table 3). Patients with higher risk had lower
expression of E-cadherin and supraglottic location of tu-
mour.
Discussion
The presence of lymph node metastases is the single
most adverse independent prognostic factor in head and
neck SCCs9. The preoperative detection of lymph node
metastases is crucial to the effective treatment of pa-
tients with laryngeal SCCs. Diagnostic imaging tech-
niques have the fundamental limitation that the meta-
stases need to have a minimal size of at least several
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Fig. 1. Low expression of E-cadherin in laryngeal squamous cell
carcinoma (Original magnification x100).
Fig. 2. High expression of E-cadherin in laryngeal squamous cell
carcinoma (Original magnification x100).
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millimeters to be detected. Even ultrasound with ultra-
sound- guided fine-needle aspiration biopsy identifies
clinically occult metastases with a sensitivity of no more
than 48 to 76%10,11. This means that small metastatic de-
posits will still be undetected, and uncertainty about the
true lymph node status of the neck will remain.
The ability to identify molecular markers from a pri-
mary tumour biopsy sample that predict cervical lymph
node metastases would enable the selection of patients at
risk for lymph node metastasis. It is accepted that the
suppression of cell- cell adhesiveness have an important
role in facilitating the dissemination of tumour cells from
the primary site and the establishment of metastasis12.
Among the several families of adhesion molecules, E-ca-
dherin has been suggested to play a role in the process of
nodal metastasis in several cancers. E-cadherin mediates
homophilic, calcium-dependent cell-cell adhesion, and its
cytoplasmic portion binds to b-catenin, which connects
the adhesion complex to the actin cytoskeleton. Down-
regulation of E-cadherin reduces cell-cell adhesion, gap-
-junction mediated communication, and prevents termi-
nal differentiation of cells- thus maintaining the ability
of continued proliferation7. The loss of E-cadherin ex-
pression in tumour tissue leading to more aggressive
phenotype because neoplastic cells have higher tendency
to spread to adjacent tissues and lymph nodes.
A reduced or absent expression or abnormal location
of E-cadherin/catenin complex has been observed in sev-
eral human carcinomas including gastric13, bladder14,
prostate15, lung16, colon17, breast18. In several studies
have been reported that abnormal expression of E-cadhe-
rin correlated with clinicopathological characteristics of
head and neck SCCs, such as lymph node metastases,
and disease-free survival. In a group of 50 patients with
head and neck SCCs Mattijssen et al. found relation be-
tween high levels of membrane- associated E-cadherin
expression and favorable outcome19. Schipper at al. ob-
served that E-cadherin expression decreased with loss of
differentiation in primary carcinomas, and that lymph
node metastases expressed a lower level of the protein,
suggesting an important role of cadherin loss in the met-
astatic process20. Simionescu et al. studied 42 cases of
oral SCCs with different sites (tongue, lips, palate, and
gums) and investigated the imunoexpression of adhesion
molecules21. The study indicated the decreasing degree of
immunostaining for E-cadherin parallel with decreasing
of oral SCCs differentiation grade. Franchi and collea-
gues observed that low expression of E-cadherin in laryn-
geal SCCs significantly correlated with the presence of
occult nodal metastases22. Eriksen et al. suggest that the
loss of adhesion – the loss of adherens junctions (E-ca-
dherin) and hemidesmosomes (integrin) – predicts the
risk of nodal metastases at the time of diagnosis23. How-
ever, a number of other studies have failed to show a rela-
tionship between E-cadherin expression and these clini-
copathological variables24. Takes et al. have examined
histological features and biological markers in 31 pa-
tients with laryngeal carcinomas25. From all the markers
investigated immunohistochemically, E-cadherin was
not relevant to prediction of lymph node metastasis. Liu
et al. have studied the markers associated with tumour
invasion and metastasis in 59 patients with laryngeal
and hypopharyngeal SCCs with node metastases26. No
relationship was found between immunolabeling of can-
cer cells for E-cadherin and the presence of lymph node
metastasis.
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TABLE 2
THE CORRELATION OF E-CADHERIN EXPRESSION WITH
CLINICOPATHOLOGIC PARAMETERS IN 80 PATIENTS WITH






Low High p valueb
Sex 0.698
Male 61 32 29
Female 19 9 10
Age (years) 0.518
£65 years 60 32 28
>65 years 20 9 11
Primary tumour site 0.263
Glottic 40 23 17
Supraglottic 40 18 22
T classification 0.079
T1 and T2 54 24 30
T3 and T4 26 17 9
N status 0.025
N0 61 27 34
N+ 19 14 5
TNM stage 0.014
I and II 40 15 25
III and IV 40 26 14
Histologic grade 0.848
G1 34 17 17
G2 and G3 46 24 22
Loco-regional recurrence 0.053
L-R rec. no 20 14 6
L-R rec. yes 60 27 33
a Low E-cadherin expression below 25, High E-cadherin expres-
sion above 25; b c2-test
TABLE 3
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In presented study, we analyzed the clinicopathologic
significance of E-cadherin expression among 80 patients
with laryngeal SCCs. E-cadherin expression was an inde-
pendent predictor of lymph node metastases. This is con-
sistent with another study on laryngeal tumours22,27, and
with large studies in other histological types metasta-
ses28–30. This suggest that the immunohistochemical de-
termination of E-cadherin expression gives us an instru-
ment to characterise the metastatic potential of these
carcinomas. That’s why E-cadherin expression may play
a role in the decision to treat a N0 neck with a neck dis-
section or with close follow-up. In our study lower ex-
pression of E-cadherin was significantly associated with
advanced clinical stage (TNM stage III and IV). There
was no significant correlation between the expression of
E-cadherin and age, sex and primary location of tumour.
Generally, E-cadherin expression was found to be high in
well differentiated cancers, but reduced in undifferenti-
ated cancers19,20,22,31. We found general, but not signifi-
cant, decline in E-cadherin expression with increasing
dedifferentiation of the tumour. This finding is in line
with those of Rodrigo et al.27
Several explanations can be suggested for conflicting
results reported in previous studies about clinical signifi-
cance of altered expression of E-cadherin in the laryngeal
SCCs12. The site and number of analysed cases, selection
of tumours (stage, tumour grade), differences in surgical
approach (extent of lymph node dissection), and differ-
ences in staining evaluation may individually or in com-
bination be responsible. E-cadherin expression is not a
static unchangeable characteristic. Also, the presence of
an adhesion molecule shown immunohistochemically
does not always suggest that this molecule is really ac-
tive. Chromosomal aberrations and protein expression
are different in some parts of the tumour compared with
others, which is usually thought to be a result of clonal
evolution.
Conclusion
Lower expression of E-cadherin in primary laryngeal
squamous cell carcinomas correlated significantly with
tumours with nodal metastases and with advanced TNM
stage. Reduction of E-cadherin expression in these carci-
nomas was an independent predictor of lymph node
metastases.
Results of the present study suggest that expression
of E-cadherin may increase our ability in identifying pa-
tients with more aggressive disease who are at consider-
able risk for occult metastases and who may benefit from
elective neck dissection. So it is very important to use
markers studied on the biopsy material of the primary
tumour that could predict the metastatic behavior. Since
metastasis is a multistep process, one single marker is
not enough, but a panel of several ones will be able to
predict metastatic behavior of the tumours. Uniform
standards are required to make the results of studies
comparable. Larger studies are needed to confirm the
role of E-cadherin expression in predicting the behavior
of laryngeal squamous cell carcinomas.
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ODNOS EKSPRESIJE E-KADHERINA SA REGIONALNIM METASTAZAMA ZA KARCINOME
LARINKSA
E-kadherin, a 120 kDa transmembranski protein, ima va`nu ulogu u tumorskoj dediferencijaciji i malignoj progresiji.
Smanjenje ili gubitak ekspresije E-kadherina je na|eno za vi{e razli~itih tumora uklju~uju}i i karcinome larinksa. Cilj
ovog istra`ivanja je da ispita prognosti~ki zna~aj promjene u ekspresiji E- kadherina za karcinome larinksa. Ekspresija
E-kadherina je analizirana imunohistohemijski kod 80 pacijenata. Rezultat imunohistohemijske ekspresije E-kadhe-
rina predstavljao je postotak obojenih }elija (0–100%). Ekspresija E- kadherina u promatranom materijalu varirala je 2
do 72 (medijana 25). U odnosu na medijanu ekspresije ispitanici su podijeljeni u dvije grupe, 41 (51.3%) tumor je klasi-
ficiran kao »niska ekspresija E-kadherina«, a ostalih 39 (48.7%) pacijenata je ~inilo grupu »visoka ekspresija E-kadhe-
rina«. Zna~ajno slabija ekspresija E-kadherina na|ena je u pacijenata sa prisutnim regionalnim metastazama u vratu
(p=0.025) i onih sa uznapredovalim stadijem bolesti (TNM stage III and IV) (p=0.014). Multivarijantnom logisti~kom
regresijskom analizom dobili smo da su ekspresija E-kadherina i primarna lokalizacija tumora nezavisni prognosti~ki
parametri za prisustvo metastaza na vratu. Imunohistokemijsko odre|ivanje ekspresije E- kadherina mo`e biti vrlo
korisno u procjeni metastaskog potencijala tumora ali ovo treba potvrditi dodatnim istra`ivanjima.
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